2026-06-14T10:38:30Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/203842024-11-28T16:53:40Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16958col_20.500.12105_16967
Repisalud
author
Sanchez-Gastaldo, Amparo
author
Kempf, Emmanuelle
author
Gonzalez del Alba, Aranzazu
author
Duran, Ignacio
2024-07-11T09:07:21Z
2024-07-11T09:07:21Z
2017-11
Sanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, Duran I. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev. 2017 Nov;60:77-89. Epub 2017 Sep 1.
10.1016/j.ctrv.2017.08.010
1532-1967
0305-7372
Cancer Treatment Reviews
http://hdl.handle.net/20.500.13003/17290
28898679
L618208952
2-s2.0-85029102409
http://hdl.handle.net/20.500.12105/20384
416192100010
Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
eng
Renal cell cancer
Targeted therapy
Angiogenesis
Monoclonal antibody
Tyrosine-kinase inhibitor
mTOR inhibitor
Immunotherapy
Systemic treatment of renal cell cancer: A comprehensive review
review article